Amyris

Amyris, Inc. engages in the provision of bioscience solutions. It offers its products to the health and wellness, clean beauty, and flavor and fragrance markets. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.

Earnings data Q1 2024

The principal business of Tara Gold Resources Corp. is the acquisition, exploration and development of high-quality precious metals projects with potential for economic commercial value. Tara Gold is currently focused on acquiring and developing properties in the natural resource belt of the Sierra Madre Occidental and other prolific areas in the states of Chihuahua, Sonora, and Sinaloa, Mexico.  Tara Gold provides investors growth exposure with a diversified exploration portfolio, multiple multi-million ounce targets and several near term production scenarios. Tara Gold owns equity positions in Cayden Resources Inc. (TSX-V: CYD) and Tara Minerals Corp. (TARM.OB), a public US company which explores and develops high-quality precious & non-precious metals and mineral projects in Mexico.

Agenus

Canopy Growth

Ginkgo Bioworks Holdings

Globalstar

Nordic American Tankers

Viking Therapeutics

Penny stocks to watch with unusual options activity this week. The post 7 Top Penny Stocks With Unusual Options Activity, Time To Buy?

7 Top Penny Stocks With Unusual Options Activity, Time To Buy?

To say that the company had a third quarter to forget is quite the understatement.

Why Amyris Stock Was Driven Into the Ground on Wednesday

Investor expectations for the third quarter were not realistic given deterioration in the macro environment and Amyris' cost structure. There was no improvement in gross margins due to high freight costs, continued production in Spain and potentially due to insourcing start-up costs and inventory accounting.

Amyris: No Relief

Amyris, Inc. (AMRS) delivered earnings and revenue surprises of -109.52% and 36.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Amyris, Inc. (AMRS) Reports Q3 Loss, Misses Revenue Estimates

Amyris, Inc. (NASDAQ:AMRS ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Han Kieftenbeld - Chief Financial Officer John Melo - President & Chief Executive Officer Eduardo Alvarez - Chief Operating Officer Conference Call Participants Colin Rusch - Oppenheimer Rachel Vatnsdal - JPMorgan Korinne Wolfmeyer - Piper Sandler Steven Mah - Cowen and Company Dan Rizzo - Jefferies Rick Schottenfeld - Schottenfeld Opportunities Fund Graham Tanaka - Tanaka Capital Management Operator Welcome to the Amyris' Third Quarter 2022 Financial Results Conference Call. This call is being webcast live on the Events page of the Investors section of the Amyris website at amyris.com.

Amyris, Inc. (AMRS) Q3 2022 Earnings Call Transcript

Sixth consecutive quarter of record consumer revenue – Consumer revenue of $46.6 million increased 98% compared to Q3 2021 Record core revenue of $71.1 million grew 49% compared to the prior year quarter "Fit to Win" revenue, cost and cash actions deliver $10 million in Q3 $180 million of new funding closed - strategic transaction on track to self-fund growth EMERYVILLE, Calif. , Nov. 8, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced financial results for the third quarter ended September 30, 2022.

AMYRIS, INC. REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS

"Fit To Win," high ROI Capex and innovative marketing are reducing cash burn equaling 19% of H2 2022 and 26% of 2023 product sales, delivering positive cash flow in 2023. Barra Bonita changes everything.  Mfg. efficiencies and 30-60% lower COGS swings Amyris Ingredients margins from negative to positive 20-50%, producing faster and more profitable Ingredient growth than we expected.

From Spending Cash To Fermenting Money: Amyris Is Fit To Profit From High ROI Plants And Innovative Marketing

Bionano Genomics

FuelCell Energy

Hall of Fame Resort & Entertainment

Meta Materials

B2Gold

It may seem a little crazy to talk about finding cheap penny stocks to buy at this time. The economy is cooling, and even blue-chip stocks are struggling to gain traction.

7 Cheap Penny Stocks to Buy Before They Pop Off

Supply chain problems appear to have caused elevated COGS and shipping and handling expenses, a problem faced by many beauty brands and DTC companies. Insourcing production and changing packaging will resolve some of these issues and help improve profitability.

Amyris: Consumer Business Cost Breakdown

EMERYVILLE, Calif. , Nov. 1, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the third quarter ended September 30, 2022, on the afternoon of Tuesday, November 8, 2022, after closing of the financial markets.

AMYRIS TO HOST THIRD QUARTER 2022 FINANCIAL RESULTS CONFERENCE CALL ON NOVEMBER 8

EMERYVILLE, Calif. , Oct. 25, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced a partnership with World Wildlife Fund (WWF), one of the world's leading conservation organizations, to support WWF's efforts to improve ocean health and reduce the impact of fishing on shark populations.

Amyris and World Wildlife Fund Announce Partnership to Protect Biodiversity

EMERYVILLE, Calif. , Oct. 24, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform, announces the launch of two new brands under its growing consumer portfolio: Stripes ™, a (peri)menopausal wellness brand founded in partnership with actress, entrepreneur and activist, Naomi Watts, and EcoFabulous ™, a clean, sustainable beauty brand designed for Gen-Z consumers, offering high performing color cosmetics and skin-care products at an accessible price point.

AMYRIS SUCCESSFULLY LAUNCHES TWO NEW CONSUMER BRANDS

A new loan facility caused some consternation.

Why Amyris Stock Tumbled This Week

EMERYVILLE, Calif. , Oct. 11, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that three of its consumer brands will be included in Sephora's launch in the United Kingdom (UK).

Amyris Brands Expanding in UK and Europe. Executing on continued accelerated growth and lower costs

Ardelyx

Transocean

Penny stocks with unusual options activity to watch today. The post Penny Stocks To Buy Now: 3 To Watch With Unusual Options Activity Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy Now: 3 To Watch With Unusual Options Activity Today

Amyris' more frequent and larger "exclusivity" deals introduce a unique, recurring catalyst to its business model that enhances profitability and requires raising our earnings estimates. We're raising our EPS estimates from ($1.19) to ($0.22)/share for 2022, from ($0.36) to ($0.09)/share for 2023, from $0.08 to $0.35/share for 2024 and from $0.62 to $0.88/share for 2025.

Recurring Marketing Exclusivity Deals Accelerate Amyris On Path To Profitability

Synthetic biology maker Amyris owns a 60% global market share for a product that's increasingly used in personal care products. Will it notch a profit in 2024?

Will Synthetic Biology Firm Amyris Post Net Income In 2024?

Advent Technologies Holdings

Avaya Holdings

Coeur Mining

Celularity

What To Watch With 5 Hot Penny Stocks This Week The post Wall Street Stock Market Today: Penny Stocks To Watch Before Fed Meeting appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Wall Street Stock Market Today: Penny Stocks To Watch Before Fed Meeting

EMERYVILLE, Calif. , Sept. 7, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that management will participate in fireside chats moderated by equity research analysts, and provide updates, at two upcoming investor conferences: H.C.

AMYRIS TO PARTICIPATE AT SEPTEMBER INVESTOR CONFERENCES

EMERYVILLE, Calif. , Aug. 31, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, published today its 2021 Environmental, Social, and Governance ("ESG") report, highlighting the company's commitment to leading the worlds transition to clean, sustainable chemistry.

AMYRIS PUBLISHES SECOND ANNUAL ESG REPORT

Lovesac Company

The experts say these stocks aren't getting half the appreciation that they deserve.

3 Stocks That Can Double Your Money According to Wall Street

Wilmington, Delaware--(Newsfile Corp. - August 9, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Amyris, Inc. (NASDAQ: AMRS) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-amyris-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Amyris, Inc.

Amyris, Inc. (NASDAQ:AMRS ) Q2 2022 Earnings Conference Call August 9, 2022 9:00 AM ET Company Participants Han Kieftenbeld - Chief Financial Officer John Melo - President & Chief Executive Officer Eduardo Alvarez - Chief Operating Officer Conference Call Participants Colin Rusch - Oppenheimer Steven Mah - Cowen & Co. Sameer Joshi - H.C. Wainwright Rachel Vatnsdal - JPMorgan Randy Baron - Pinnacle Graham Tanaka - Tanaka Capital Management Operator Welcome to the Amyris Second Quarter 2022 Financial Results Conference Call.

Amyris, Inc. (AMRS) CEO John Melo on Q2 2022 Results - Earnings Call Transcript

Amyris, Inc. (AMRS) delivered earnings and revenue surprises of -50% and 20.06%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Amyris, Inc. (AMRS) Reports Q2 Loss, Lags Revenue Estimates

Record consumer revenue of $43 million increased 108% compared to Q2 2021 Ingredients sold out in first half with $15 million backlog to be supplied in H2 Cost actions and price increases to deliver $50 million of EBITDA improvements in H2 $700 million non-equity funding and earnout provides liquidity to sustained profitability EMERYVILLE, Calif. , Aug. 9, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced financial results for the second quarter ended June 30, 2022.

News for Amyris Stock (AMRS)